BlossomHill's BH-30643 Shows 45% ORR in EGFR C797S NSCLC, Phase 2 Planned for 2027
BLSM sits 49% above its 52-week low of $15.6.
Summary
BlossomHill presented updated Phase 1/2 SOLARA data at IASLC 2026 showing BH-30643 achieved a 45% objective response rate (18/40) and 88% disease control rate in EGFR C797S-positive NSCLC patients resistant to prior EGFR inhibitors. The drug demonstrated a favorable safety profile with only 9% dose reductions and 3% discontinuations. This is the first detailed efficacy readout for the lead asset in a population with no approved targeted therapies, following the FDA Fast Track designation granted in August. The company plans to initiate a global Phase 2 study in Q1 2027. The data validate the OMNI-EGFR mechanism and support advancement toward registration, though durability remains to be confirmed with longer follow-up.
At the time of this announcement, BLSM was trading at $23.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $666.2M. The 52-week trading range was $15.60 to $23.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.